MedTrace Logo

Hydrocortisone Use After Etomidate in Intensive Care

NCT00862381 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2010-07-26

No results posted yet for this study

Summary

the objective of the study is to assess the value of substitution with 200mg/24h of hydrocortisone for 48 hours for patients in intensive care who have received a single injection of etomidate

Conditions

  • Patient Admitted in Reanimation

Interventions

DRUG

Hydrocortisone

hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment

DRUG

Placebo

NaCl 0.9%

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Christophe PH, BROUX · University Hospital of Grenoble, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00862381 on ClinicalTrials.gov